Gleevec (known as Glivec in the EU, Australia and Latin America) has been hailed as something of a miracle drug, helping to nearly double the rate of people with chronic myeloid leukaemia (CML) who survive at least five years. Approved by the US Food and Drug Administration (FDA) in 2001, the drug has helped that survival rate increase from 31% in 1993 to 59% for those diagnosed between 2003 and 2009. So important was the drug for public health in India that in 2013 Gleevec’s maker Novartis was refused a patent protecting the drug in the country despite its having equivalent patents in many other countries.
Gleevec is Novartis’s biggest selling product by far, generating $4.7 billion worldwide in 2014, almost twice as much as the company’s second best-seller, multiple sclerosis treatment Gilenya (fingolimod).
Te main US patent covering the drug expired on January 4 (paediatric exclusivity protects the drug until July 4), and with at least three companies vying to make a generic version, or already having a generic on the market, Novartis has been working hard to prepare itself for a big hit.
To compensate for potential lost profits, Novartis starting switching patients to another CML drug, Tasigna (nilotinib), the compound patent for which doesn’t expire until 2023. Meanwhile, in Japan, Daiichi Sankyo has been marketing generic imatinib tablets, while Teva has received marketing authorisation from the European Medicines Agency (EMA) to make and sell generic versions of Gleevec. In the US, Novartis settled patent litigation with Sun Pharma—with the terms of the settlement allowing Sun to launch a generic Gleevec in the US on February 1, 2016, despite the main patent’s expiry in January this year.
Lantus (insulin glargine [rDNA origin] injection) is Sanofi’s best-performing medicine, not just in its diabetes portfolio, but across the board. Along with its partner product—the Lantus SoloStar pen— Lantus made $7.1 billion of Sanofi’s total $38.2 billion net sales worldwide in 2014, representing more than 18% of the company’s takings. Last year’s 11% growth of Sanofi’s diabetes division in the fourth quarter was driven by Lantus, the company said. Tis is an important drug for Sanofi.
However, the France-based company has a strategy in place to help prop up its diabetes division aſter Lantus’s US expiry in February. Last August, Sanofi bought the rights to Mannkind Corporation’s Afrezza, an inhalable form of insulin. Afrezza, which was profiled in
Some of the big pharma are poised to launch their own versions of Lantus. Eli Lilly and Boehringer Ingelheim have together developed their own insulin glargine injection, called Basaglar, which received marketing authorisation from the EMA last September, and has been granted tentative approval by the FDA. Merck and Samsung Bioepis are also working together to develop a version of Lantus.
Actavis has a lot at stake with its Alzheimer’s drug Namenda, which it acquired aſter merging with Forest Laboratories last July. According to IMS Health, Namenda made worldwide sales of $1.7 billion in the 12 months ending June 30, 2014. Te main US patent covering the drug expires on April 11, although paediatric exclusivity remains until October 11. Te terms of certain Forest settlement agreements allow some generic companies to launch versions of Namenda three months earlier than this date, in July. Faced with possibly losing a sizable portion of its profits, Forest put a long-term strategy into effect last year. In February 2014, it announced that it would take Namenda off the market in August, and that it would sell the extended release formulation of Namenda—Namenda XR—exclusively. Te main US patent covering Namenda XR expires in 2025.
LSIPR’s March 2013 newsletter, launched in the US in February 2015, just in time for Lantus’s expiry.
Sanofi has also been developing a new diabetes product—Toujeo (insulin glargine), which is similar to Lantus. It is being reviewed by the FDA. If accepted, Toujeo will launch in the US in the first half of 2015.
In a statement last November, Sanofi said it expected its diabetes sales in the next four years to be fairly flat, assuming “substantial conversion” of patients from Lantus to Toujeo.
However, Forest’s patient-switching strategy wasn’t looked upon favourably by New York state attorney general Eric Schneiderman, who, last September, filed an anti-competition lawsuit against Actavis. He argued that the company was “forcing” patients from the twice-a-day pill to the once-daily formulation of Namenda XR. Te company was later barred from implementing its strategy.
Nevertheless, at an investor conference in January, Actavis chief executive Brett Saunders was quoted by the Wall Street Journal’s Pharmalot blog as saying that 40% of patients had made the switch and that the company has a “very good shot” at getting that number to 65% to 70% by the summer of 2015.
Actavis has another trick up its sleeve. In partnership with Californian pharma company Adamas, it has developed Namzaric, a fixed dose combination of Memantine XR and donepezil hydrochloride (the active ingredient in Pfizer’s Alzheimer’s drug Aricept, which lost patent protection in 2010). Te FDA approved Namzaric last December.
Bristol-Myers Squibb (BMS), which makes Abilify (aripiprazole), has a lot at stake with its depression drug. Te product is New York- based BMS’s biggest seller, generating more than $2 billion in worldwide sales for the company
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44